In steroid-refractory GvHD, what most influences your second-line treatment choice?
Mogamulizumab for adult T-cell leukemia/lymphoma: a literature review. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42305457
Mogamulizumab may aid ATLL treatment, notably in CCR4 mutations. Clinicians should monitor for adverse effects like infusion reactions, rashes, and infections.
Mogamulizumab may benefit ATLL patients, especially with CCR4 mutations. Adverse effects include infusion reactions, rashes, infections, and increased GVHD risk pre-allo-SCT.
Unusual Infections following Haploidentical Hematopoietic Stem cell Transplant in a Case with severe Aplastic Anaemia'. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42253347
Explore a severe aplastic anemia case post-transplant with infections like pulmonary nocardiosis, refractory giardiasis, and viral reactivations, managed alongside GVHD.
A case of severe aplastic anemia post-haploidentical transplant developed multiple infections, including pulmonary nocardiosis, refractory giardiasis, and viral reactivations (cytomegalovirus and adenovirus), managed alongside GVHD.
Comparison of chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for steroid-refractory acute graft-versus-host disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41550930/
In conclusion, no significant differences were observed in efficacy or adverse events between chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for the treatment of SR-aGVHD. Further studies with larger cohorts...
This retrospective study found similar day-28 response rates, safety, one-year survival, and non-relapse mortality between humanized xenopax and chimeric basiliximab for steroid-refractory acute graft-versus-host disease after allogeneic transplantation.
Case Report: Transfusion-associated graft-versus-host disease in severe combined immunodeficiency - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41601678/
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but fatal blood transfusion complication, with a mortality rate of 90-100%. Severe combined immunodeficiency (SCID) is a life-threatening primary immunodeficiency with profound cellular...
Case report of infant with SCID due to novel IL2RG mutation who developed fatal transfusion-associated graft-versus-host disease after non-irradiated transfusion, highlighting prevention importance and potential early markers like lymphocyte and eosinophil counts.